12 Amendments of Piernicola PEDICINI related to 2018/2775(RSP)
Amendment 5 #
Recital C
C. whereas Cannabis products that are used for medicinal purposes are broadly referred to as “medical cannabis”the term “medical cannabis” may refer either to the general use of cannabis for medicinal purposes or to the treatment of symptoms of illness and other conditions with the whole, unprocessed marijuana plant or its basic extracts; whereas the latter mainly refers to off-label pharmacotherapy, which is regulated in some Member States, and it does not normally implies consumption through smoking, rather through ingestion or inhalation from a vaporiser; whereas, nonetheless, this term is largely undefined from a legal point of view and it remains ambiguous and open to interpretations;
Amendment 10 #
Recital C a (new)
Ca. whereas “cannabis-based medicines” are medicinal products, based on THC, on CBD and/or on other cannabinoids, supported by clinical trials and approved by a regulator, either EMA or other national regulatory agencies;
Amendment 12 #
Recital E
E. whereas EU countries differ widely in their legislation with respect toapproach to cannabis legislation, including the legislation on cannabis for medicinal purposes, as well as allowed quantities of medicinal cannabis andfor example on the maximum levels of THC and CBD allowed concentrations;
Amendment 13 #
Recital E a (new)
Ea. whereas there is mounting public debate about cannabis policy, but no scientific evaluation of the impact of current legislation;
Amendment 15 #
Recital G
G. whereas the policy landscape for medical cannabis and general attitude to cannabis is evolving both in the EU and worldwide; whereas there is still misunderstanding around the different uses of cannabis even among national administrations, often confusing the legalisation of cannabis for recreational use with the necessity to provide safe and legal access to cannabis for medical purposes to all patients in need;
Amendment 22 #
Recital K
K. whereas there is limited evidence that cannabis or cannabinoids are effective for increasing appetite and decreasing weight loss associated with HIV/AIDS, improving clinician-measured multiple sclerosis spasticity symptoms, improving symptoms of Tourette syndrome, improving symptoms of posttraumatic stress disorder;
Amendment 27 #
Recital L
L. whereas the medical potentialities of cannabis, as well as the long-term risks, have not been sufficiently proven by scientific research yet; whereas official data about research and research funding on medical cannabis remain scant. Research on medical cannabis has received no direct support during the current research programme in the EU and there is little coordination about research projects on medical cannabis in Member States;
Amendment 36 #
Paragraph 1
1. Stresses the need forCalls on the Commission and national authorities to drawwork together to provide for a clear distinction betweengal definition of medical cannabis, and other applications of cannabito draw a clear distinction with the non-medical applications (e.g. recreational or industrial); further stresses the need to create public awareness on the differences among these uses;
Amendment 42 #
Paragraph 1 a (new)
1a. Calls on the Commission and the Member States to address the issue of all the hemp-derived products present on the EU market which are bought without prescription, but often considered as having medical properties and/or treated as substitutes for medicines; further calls on the Commission and the Member States to work together with EFSA in this respect to guarantee comsumers’ and patients’ safety, starting from ensuring an accurate and clear labelling of these products and their content;
Amendment 46 #
Paragraph 2
2. Considers that research on medical cannabis has been underfunded and should be properly addressed under the next Framework Programme 9 to explore the possible uses of THC, CBD, and other cannabinoids for medical treatment, as well as their effects on the human body, including lessons drawn from the experience of off-label prescribing of cannabis;
Amendment 48 #
Paragraph 3
3. Calls on the Commission and Member States to address the regulatory and, financial and cultural barriers which weigh on scientific research in the use of cannabis for medicinal purposes;
Amendment 80 #
Paragraph 10
10. Underlines how a comprehensive regulation of medical cannabis would translate in additional resources for public authorities, would limit the black market for medical cannabis consumption, would, would ensure product quality and accurate labelling to help control points of sale, would limit the access of this substance to minors and would give a legal certainty and safe access to patients for its medicinal use - with particular precautions for young people and pregnant women;